Effect of kunxian capsule and leflunomide on IgA nephropathy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019606

Enrollment

Unknown

Registered

2018-11-19

Start date

2018-12-01

Completion date

Unknown

Last updated

2018-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgA nephropathy

Interventions

1:Kun-Xian Capsule

2:Leflunomide

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Renal biopsy proved to be IgA nephropathy; 2. aged 15~75 years old; 3. According to the KDIGO guidelines, patients with IgA nephropathy do not need to use glucocorticoid and immunosuppressive agents; 4. Volunteer for clinical trials and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with other immune diseases; 2. Allergic to this drug; 3. Acute renal insufficiency; 4. Liver function damage; 5. gestation; 6. receiving other immunosuppressants drug.

Design outcomes

Primary

Measure	Time frame
the 24-hour urinary protein;albumin;creatinine;	—

Secondary

Measure	Time frame
ACR;Urine RBC;hemoglobin;	—

Countries

China

Contacts

Public ContactFAN JUNMING

The First Affiliated Hospital of Chengdu Medical College

junmingfan@163.com+86 13908199530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026